CENGILD G.I Medical Centre lauded at Healthcare Asia Awards 2026

The centre was recognised for advancing endoscopic innovation and multidisciplinary integration.

CENGILD G.I Medical Centre received an accolade in the Specialty Hospital of the Year (Gastroenterology) - Malaysia category at the Healthcare Asia Awards 2026. This recognises its sustained progress in gastroenterology and hepatology as well as its continued advancement in endoscopic innovation and coordinated multidisciplinary care.

Established as a dedicated gastroenterology and hepatology facility, the centre built its practice around subspecialty care for gastrointestinal, liver, and metabolic conditions. Over eight years, it expanded its service scope to include more than 15 medical disciplines such as cardiology, colorectal surgery, oncology, otorhinolaryngology, gynaecology, internal medicine, general surgery, bariatric surgery, urology, radiology, anaesthesiology, and critical care. This structure supports coordinated management for patients with complex or multi-system conditions within a single facility.

Advanced diagnostic and therapeutic endoscopy forms a core part of its clinical work. The centre provides endoscopic ultrasound and endoscopic retrograde cholangiopancreatography for pancreaticobiliary and gastrointestinal conditions. More than 7,000 endoscopic procedures are performed annually, covering preventive screening and therapeutic intervention.

The hospital introduced ENAD AI Endoscopy, becoming the first hospital in Malaysia to deploy this artificial intelligence-assisted system during endoscopic procedures. The system supports lesion detection and standardises image assessment to reduce operator variability. An enteroscope is also utilised for the management of small bowel conditions that require extended visualisation beyond conventional endoscopy.

Capabilities were further extended to bariatric and metabolic endoscopy, providing minimally invasive options for weight and metabolic health management. In July 2025, the centre was appointed as an official SPATZ Gastric Balloon Training Centre, formalising its role in clinical training for this procedure.

Operational growth was reflected in its listing on the ACE Market of Bursa Malaysia Securities Berhad. In 2025, Cengild recorded year-on-year growth in financial performance for FYE2025. The Group’s revenue of RM80.00m represents a strong increase of 19.7% compared to FY2024, supported by disciplined execution, operational efficiency improvements, and expanded service capacity. Revenue increased in line with higher inpatient and surgical volumes, further strengthened by the full-year contribution from renovated facilities that improved patient throughput and supported a more diverse clinical portfolio. Development is underway for CENGILD Specialist Hospital, which will add advanced imaging and therapeutic services, including CT, MRI, angiography, fluoroscopy, PET-CT, radiotherapy systems, ultrasound, X-ray, mammography, audiology, and bone densitometry. Additional specialties are planned as part of the expansion, supported by operating theatres, an oncology daycare centre, and inpatient services.

Healthcare Asia Awards is an awards programme focused on acknowledging exceptional hospitals across Asia that redefine the standards of excellence in the healthcare industry. It proudly shines a spotlight on Asian hospitals that consistently go beyond conventional boundaries to provide top-tier patient care and have a lasting impact on their local communities.

The Healthcare Asia Awards is presented by Healthcare Asia Magazine. To view the full list of winners, click here. If you want to join the 2027 awards programme and be acclaimed for your organisation's remarkable initiatives and contributions to the healthcare industry, please contact Julie Anne Nuñez-Difuntorum at [email protected].